Tirzepatide demonstrates superior weight loss results in clinical trials, with patients losing 15-22% of body weight compared to 10-15% with semaglutide, though both medications are highly effective GLP-1 options
Nausea, reflux, and low blood sugar risk can also increase, especially early in therapy or after dose changes
Studies are also underway in moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes (a separate ~10,000-participant CVOT), and metabolic dysfunction-associated steatotic liver disease (MASLD)
SMGT-GLP-1, with its unique mechanism of action, has already achieved significant results in diabetes treatment and weight management
liraglutide at low doses alone, did not demonstrate the greater efficacy of the combination therapy, as the area of VAT was reduced in all the three treatments arms without inter-groups differences [59, 60]
Contact an experienced Chicago motorcycle accident lawyer at TorHoerman Law today to find out how we can help